Sonja Weiser Dr. Pmp
About Sonja Weiser Dr. Pmp
Dr. Sonja Weiser is a Senior Director of Clinical Operations with over 20 years of experience in the healthcare industry, focusing on drug development and clinical research. She has held various leadership roles in prominent organizations and advocates for process improvement and effective people management within clinical operations.
Current Role at Insmed
Dr. Sonja Weiser serves as the Senior Director of Clinical Operations at Insmed Incorporated. She has held this position since 2020, overseeing clinical operations and contributing to the company's strategic objectives in drug development. Her role involves managing clinical trials and ensuring compliance with regulatory standards.
Previous Experience in Clinical Operations
Prior to her current role, Dr. Weiser worked at Insmed as the Director of Clinical Operations Europe from 2016 to 2020. She has extensive experience in clinical operations, having held various positions at organizations such as SynteractHCR, Harrison Clinical Research, and GSK. Her roles have included responsibilities in managing clinical research teams and operations across Europe.
Educational Background
Dr. Weiser studied at Ludwig-Maximilians-Universität München, where she achieved her PhD. She has also been pursuing a Bachelor of Pharmacy (B.Pharm.) at the same institution since 1996. Additionally, she obtained her Project Management Professional (PMP) certification from the Project Management Institute in 2016.
Leadership Philosophy and Advocacy
Dr. Weiser believes in managing by example as a leadership philosophy. She advocates for process improvement on an international level within clinical operations. Her emphasis on people management and open communication is recognized as a key factor for success in clinical research.
Specialization in Clinical Research
With over 20 years of experience in the healthcare industry, Dr. Weiser specializes in clinical research related to oncology, immunology, infectious diseases, respiratory indications, and rare/orphan diseases. Her expertise contributes significantly to advancing clinical trials and drug development in these areas.